Yokohama, Japan
Yokohama, Japan

Time filter

Source Type

Sugiyama N.,Hamamatsu Photonics K K | Asai Y.,ReproCELL | Yamauchi T.,Hamamatsu Photonics K K | Kataoka T.,Hamamatsu Photonics K K | And 4 more authors.
Biomedical Optics Express | Year: 2012

There is a need for a noninvasive technique to monitor living pluripotent stem cell condition without any labeling. We present an optical imaging technique that is able to capture information about optical path difference through the cell and cell adhesion properties simultaneously using a combination of quantitative phase microscopy (QPM) and interference reflection microscopy (IRM) techniques. As a novel application of QPM and IRM, this multimodal imaging technique demonstrated its ability to distinguish the undifferentiated status of human induced pluripotent stem (hiPS) cells quantitatively based on the variation of optical path difference between the nucleus and cytoplasm as well as hiPS cellspecific cell adhesion properties. © 2012 Optical Society of America.


PubMed | Juntendo University, Kanagawa Childrens Medical Center, St Lukes International Hospital, Ibaraki Childrens Hospital and 12 more.
Type: Clinical Trial | Journal: International journal of hematology | Year: 2016

Residual disease (RD) after induction chemotherapy may predict clinical outcome in acute myeloid leukemia (AML). In the present study, we investigated the prognostic significance of RD detected by multidimensional flow cytometry (MDF) among 34 children treated for AML in a clinical trial (JPLSG AML-05) in Japan. Bone marrow samples were analyzed at the points of the end of the first induction course (BMA-1) and second induction course (BMA-2) by MDF. RD was evaluated by detecting the immature cells showing abnormal antigen expression pattern; CD34(+), CD15(+), CD7(+). Thirteen (39.4 %) of 34 patients at BMA-1 and 8 (27.6 %) of 34 at BMA-2 had RD levels 0.1 %. There was no significant difference in 3y-EFS and 3y-OS between patients with RD levels 0.1 % and those with RD levels <0.1 % (53.8 versus 70.0 %, P = 0.30 and 50.0 versus 66.7 %, P = 0.27, respectively). However, IR cytogenetics and negative FLT3-ITD patients with RD levels 0.1 % exhibited significantly lower 3y-EFS and 3y-OS than those with RD levels <0.1 % (33.3 versus 83.3 %, P = 0.02 and 20.0 versus 76.9 %, P = 0.005, respectively). Our study suggests that RD shows prognostic relevance in pediatric patients with IR cytogenetics and negative FLT3-ITD AML.


The cell observation using a conventional well plate takes much costs. Each well 3 being opened at a top plate 2a of the well plate 1 has a diameter reduced portion 32 which inner circumferential surface 32a is conically hollowed. At a lower portion of the diameter reduced portion 32 is formed an inserting hole 33. In a detecting portion 4, an outer circumferential surface of a round-bar reference electrode 41 is covered by an insulating portion 42. The detecting portion 4 has an upper end portion 4a and a lower end portion 4b which outer circumferential surface is exposed to an outside without being covered by an insulating portion 42. On an upper side above the lower end portion 4b is formed a diameter expanded portion 4c in which an outer circumferential surface of the insulating portion 42 is covered with a measuring electrode 43. The detecting portion 4 is fixed to a well 3 whose diameter expanded portion 4c is inserted into an inserting hole 33 and its upper end portion 4a is contained in the well 3. In the detecting portion 4, the upper end surface 43a of the measuring electrode 43 is communicated with an inner circumferential surface 32a of the diameter reduced portion 32 positioned in an edge surrounding portion of the inserting hole 33.


Patent
ReproCELL and Nissan Chemical Industries Ltd. | Date: 2011-12-01

An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R^(1 )to R^(8 )are as defined in the description).


Patent
Nissan Chemical Industries Ltd. and ReproCELL | Date: 2010-08-18

An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided. A method for expanding hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises culturing hematopoietic stem cells and/or hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) (wherein X, Y, X, Ar^(1), R^(1), R^(2), R^(3), R^(4), R^(5), R^(6) and R^(7) are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.


Patent
ReproCELL and Nipro Corporation | Date: 2010-07-23

A cellular electric potential measuring container includes a container body and an electrode substrate, the electrode substrate being attached to a lower end of the container body so as to form a plurality of wells. The container body is made from resin and comprises a plurality of tubular portions whose upper and lower ends are open, each of the tubular portions comprises in an inner cavity a measurement portion tapered toward the lower end and having a measurement hole at the lower end, and further on an inner wall at least two retaining means retaining the measurement portion. The electrode substrate comprises a substrate body, with a plurality of measurement electrodes and a plurality of reference electrodes being disposed on one surface of the substrate body. The container body is attached to the surface of the substrate body on which the measurement electrodes and the reference electrodes are disposed, such that the measurement electrodes are exposed through the measurement holes.


Patent
Nipro Corporation and ReproCELL | Date: 2012-05-30

An object of the present invention is to provide a cellular electric potential measuring container with which an accurate measurement result can be readily obtained by bringing a cell into contact with a fine measurement electrode in cellular electric potential measurement using a cellular electric potential measuring container. The present invention provides a cellular electric potential measuring container comprising a container body and an electrode substrate, the electrode substrate being attached to a lower end of the container body so as to form a plurality of wells, the cellular electric potential measuring container being for measuring cellular electric potential after being mounted on an electric potential measuring device and, wherein the container body is made from resin and comprises a plurality of tubular portions whose upper and lower ends are open, each of the tubular portions comprises in an inner cavity a measurement portion tapered toward the lower end and having a measurement hole at the lower end, and further on an inner wall at least two retaining means retaining the measurement portion, the electrode substrate comprises a substrate body, with a plurality of measurement electrodes and a plurality of reference electrodes being disposed on one surface of the substrate body, and the container body is attached to the surface of the substrate body on which the measurement electrodes and the reference electrodes are disposed, such that the measurement electrodes are respectively exposed through the measurement holes.


Patent
Nissan Chemical Industries Ltd. and ReproCELL | Date: 2013-10-09

An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R^(1) to R^(8) are as defined in the description).


Asai Y.,ReproCELL | Tada M.,Japan Building Research Institute | Tada M.,Kyoto University | Otsuji T.G.,Japan Building Research Institute | And 2 more authors.
Current Stem Cell Research and Therapy | Year: 2010

Human pluripotential stem cells including both embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) possess self-renewing potency and pluripotentency and can differentiate into virtually any somatic cell type. These features are a distinct advantage for the generation of specific types of human tissue cells in vitro for continuous use in drug development. Recently, an assay system for drug-induced QT interval prolongation using hESC/hiPSC-derived cardiomyocytes and microelectrode arrays (MEA) has been developed. Drug-induced QT interval prolongation (DIQTIP) can lead to sudden cardiac death and is a major safety concern for the drug industry. Regulatory authorities such as the US FDA and the European Medicines Agency require in-vitro testing of all drug candidates to identify potential risk of DIQTIP prior to clinical trials. To reduce the risk of DIQTIP, a routine assay system for in vitro electrophysiological properties using cell-based assays is effective and necessary in early phase of drug discovery. This review discusses developments over the last couple of years for a qualified drug testing method and provides some examples of how hESC/hiPSC-derived cardiomyocytes are beginning to find a practical use for drug discovery and development. © 2010 Bentham Science Publishers Ltd.


Loading ReproCELL collaborators
Loading ReproCELL collaborators